|Mr. Andrew McLean||CEO & Exec. Director||885.18k||N/A||N/A|
|Mr. Darren Smith M.B.A., B.Bus., FCPA||CFO & Company Sec.||559.13k||N/A||52|
|Mr. Nigel Lange||Chief Commercial Officer||749.75k||N/A||N/A|
|Mr. Robert Hardie||Global Head of Operations||545.85k||N/A||N/A|
|Dr. Thomas Duthy Ph.D.||Global Investor Relations Mang.||N/A||N/A||N/A|
Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia Pacific, Europe, the Middle East and Africa, and North and South America. Its lead product includes SIR-Spheres Y-90 resin microspheres, a targeted radiation therapy for the treatment of liver tumours. The company is headquartered in North Sydney, Australia.
Sirtex Medical Limited’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 8.